Corvus Pharmaceuticals (CRVS) Accounts Payables (2015 - 2026)

Corvus Pharmaceuticals' Accounts Payables history runs 12 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 259.1% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (up 259.1% YoY), while the FY2025 annual figure was $2.5 million, down 3.52% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.7 million, up from $2.5 million in the prior quarter.
• The five-year high for Accounts Payables was $4.7 million in Q1 2026, with the low at $730000.0 in Q2 2025.
• The 5-year median for Accounts Payables is $1.9 million (2024), against an average of $2.1 million.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables slumped 66.78% in 2023, then surged 259.1% in 2026.
• Corvus Pharmaceuticals' Accounts Payables stood at $2.0 million in 2022, then fell by 22.82% to $1.5 million in 2023, then jumped by 69.31% to $2.6 million in 2024, then fell by 3.52% to $2.5 million in 2025, then soared by 88.56% to $4.7 million in 2026.
• Business Quant data shows CRVS's Accounts Payables at $4.7 million in Q1 2026, $2.5 million in Q4 2025, and $1.2 million in Q3 2025.